RT Journal Article
SR Electronic
T1 Assessment of hypoxia in recurrent GBM with 18F-fluoromisonidazole PET, MRI and MRSI: Preliminary results
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1257
OP 1257
VO 53
IS supplement 1
A1 Li, Yan
A1 Jalilian, Laleh
A1 Seo, Youngho
A1 Hernandez Pampaloni, Miguel
A1 Wilson, David
A1 Vanbrocklin, Henry
A1 Prados, Michael
A1 Nelson, Sarah
YR 2012
UL http://jnm.snmjournals.org/content/53/supplement_1/1257.abstract
AB 1257 Objectives The aim of this study was to assess the correlation between 18F-fluoromisonidazole (FMISO)-PET and MRI/MRSI parameters in patients with glioblastoma multiforme (GBM) in whom disease progression was suspected. Methods Three patients diagnosed with GBM who received radiotherapy and temozolomide were studied. The MR protocol included an axial fluid attenuated inversion recovery, pre- and post-gadolinium T1-weighted spoiled gradient echo, diffusion-weighted and perfusion-weighted images, and 3D lactate-edited 1-H MRSI. 18F-FMISO was administered intravenously and (from 110+/-10 minutes post-injection) a single field-of-view emission scan was acquired for 20 minutes. The tissue-to-blood ratio (T/B) was calculated as the tissue activity divided by the average blood activity. Results One patient was confirmed surgically to have disease progression; the remaining two patients were stable based upon subsequent clinical follow-up. Figure 1 shows sample PET, MR images and MRSI. Higher cerebral blood volume (CBV) and percent ΔR2* signal height (PH) than those in normal-appearing white matter was found for the patient who had a region with T/B>=1.1. There was no lactate in the MRSI data from these subjects. Conclusions This study demonstrated the successful imaging of GBM with 18F-FMISO. Higher CBV and PH were found in a region with T/B>=1.1. This could reflect the formation of new blood vessels secondary to regional hypoxia associated with rapidly proliferating GBM